title: [Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease].
abstract: OBJECTIVE
  The use of complementary and alternative medicine (CAM) is increasing in last years. Studies performed out of Spain have reported rates of CAM use of 40-50% among IBD patients. There are no available data on drug abuse among IBD patients. The aims of our study were to evaluate the rate and associate factors of CAM use and drug abuse among Spanish IBD patients.
  
  
  METHODS
  Anonymous, structured questionnaire, administered to consecutive patients with IBD of at least 2 years of duration, seen in a IBD outpatient clinic.
  
  
  RESULTS
  Twenty-six per cent of the 214 included patients reported having used CAM. No associated factors were found, although patients with ulcerative colitis tended to a higher rate of CAM use. Ten per cent of patients admitted to consume drugs, mainly cannabis derivatives. Younger age and college and universitary degree were the only factors associated to cannabis consumption.
  
  
  CONCLUSIONS
  The rate of CAM use in IBD patients from a Spanish referral centre is lower than those described in other countries. About 10% of IBD patients consume cannabis, but only one third of them inform their physician about it.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.
authors.forename: Esther
authors.initials: E
authors.lastname: García-Planella
authors.forename: Laura
authors.initials: L
authors.lastname: Marín
authors.forename: Eugeni
authors.initials: E
authors.lastname: Domènech
authors.forename: Isabel
authors.initials: I
authors.lastname: Bernal
authors.forename: Míriam
authors.initials: M
authors.lastname: Mañosa
authors.forename: Yamile
authors.initials: Y
authors.lastname: Zabana
authors.forename: Miquel A
authors.initials: MA
authors.lastname: Gassull
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy; D015897:Comorbidity; D000529:Complementary Therapies / Q000706:statistics & numerical data*; D003469:Culture; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D002189:Marijuana Abuse / Q000453:epidemiology / Q000523:psychology; D008385:Marijuana Smoking / Q000453:epidemiology; D008875:Middle Aged; D010817:Physician-Patient Relations; D012651:Self Medication; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D012959:Socioeconomic Factors; D013030:Spain; D019966:Substance-Related Disorders / Q000453:epidemiology* / Q000523:psychology; D011795:Surveys and Questionnaires; D014342:Truth Disclosure
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents